



**GUIDELINES FOR TREATMENT OF NATIVE VALVE INFECTIVE ENDOCARDITIS in PATIENTS
on PEDIATRIC SERVICES**

(Infectious Diseases consultation is STRONGLY recommended)

Empiric therapy (prior to confirmation of pathogen):

- [Vancomycin IV](#)³ + **Ceftriaxone** 100 mg/kg/dose IV q24h (max: 2 g/dose)
- **NOTE: Cefepime** 50 mg/kg/dose IV q8h¹ (max: 2 g/dose) should be used instead of ceftriaxone in burn patients and IV drug users

Gentamicin goals:

- Gentamicin is used for gram positive synergy
- Traditional gentamicin synergy dosing (1 mg/kg/dose IV q8h) is preferred in pediatric patients
- Gentamicin peak goal 3-5 mcg/dL and trough goal <1 mcg/dL

Definitive Therapy (Once Pathogen is Identified)

Pathogens		Antibiotic Therapy (renal dose adjustments may be necessary) ¹	Duration	Comments
Viridans group streptococci	Penicillin MIC ≤0.12 mg/L	Preferred: Penicillin G 50,000 units/kg/dose IV q4h ^{1,2} (max: 3 million units/dose) OR Ceftriaxone 100 mg/kg/dose IV q24h (max: 2 g/dose)	4 weeks	<ul style="list-style-type: none"> • Avoid the 2 week regimen with gentamicin in patients with known cardiac or extracardiac abscess, CrCl <20 mL/min, impaired 8th cranial nerve function, or <i>Abiotrophia</i>, <i>Granulicatella</i>, or <i>Gemella</i> spp. infection.
		Preferred (alternative): Penicillin G 50,000 units/kg/dose IV q4h ^{1,2} (max: 3 million units/dose) + Gentamicin IV ⁴ OR Ceftriaxone 100 mg/kg/dose IV q24h (max: 2 g/dose) + Gentamicin IV ⁴	2 weeks	
		Alternative for Severe PCN Allergy: Vancomycin IV ³	4 weeks	
OR <i>Streptococcus galloyticus (bovis)</i>	Penicillin MIC >0.12- <0.5 mg/L	Preferred (if susceptible): Ceftriaxone 100 mg/kg/dose IV q24h (max: 2 g/dose)	4 weeks	
Preferred (alternative): Penicillin G 50,000 units/kg/dose IV q4h ^{1,2} (max: 4 million units/dose) + Gentamicin IV ⁴ for first 2 weeks ¹				
Alternative for Severe PCN Allergy: Vancomycin IV ³				
	Penicillin MIC ≥0.5 mg/L	Preferred (if susceptible): Ceftriaxone 100 mg/kg/dose IV q24h (max: 2 g/dose) + Gentamicin IV ⁴	4-6 weeks	<ul style="list-style-type: none"> • 4 week duration indicated only if symptoms of infection are <3 months in duration.
		Preferred (alternative): Penicillin G 50,000 units/kg/dose IV q4h ^{1,2} (max: 4 million units/dose) + Gentamicin IV ⁴		
		Alternative for Severe PCN Allergy: Vancomycin IV ³		
Pathogens		Antibiotic Therapy (renal dose adjustments may be necessary) ¹	Duration	Comments
Enterococci strains susceptible to penicillin and gentamicin		Preferred: Ampicillin 75 mg/kg/dose IV q6h ¹ (max: 3 g/dose)	4-6 weeks	<ul style="list-style-type: none"> • Request susceptibility testing for penicillin if used for therapy.

	<p>+ Gentamicin IV⁴ OR Penicillin G 50,000 units/kg/dose IV q4h^{1,2} (max: 4 million units/dose) + Gentamicin IV⁴</p>		<ul style="list-style-type: none"> Ampicillin + aminoglycoside regimen: 4-week duration indicated only if symptoms of infection are <3 months in duration. Ampicillin + ceftriaxone regimen should be considered in patients with renal insufficiency
	<p><u>Preferred (alternative):</u> Ampicillin 75 mg/kg/dose IV q6h¹ (max: 3 g/dose) + Ceftriaxone 50 mg/kg/dose IV q12h (max: 2 g/dose)</p>	6 weeks	
	<p><u>Alternative for Severe PCN Allergy:</u> Vancomycin IV³ + Gentamicin IV 1 mg/kg/dose q8h¹</p>		
Enterococci strains susceptible to penicillin and resistant to gentamicin	<p><u>Preferred:</u> Ampicillin 75 mg/kg/dose IV q6h¹ (max: 3 g/dose) + Ceftriaxone 50 mg/kg/dose IV q12h (max: 2 g/dose)</p>	6 weeks	<ul style="list-style-type: none"> Streptomycin peak goal 20-35 mg/L and trough goal <5 mg/L.
	<p><u>Alternative for Severe PCN Allergy (for streptomycin susceptible):</u> Vancomycin IV³ + Streptomycin 10 mg/kg IV q12h¹ (max: 1 g/dose)</p>		
	<p><u>Alternative for Severe PCN Allergy (for streptomycin resistant):</u> Consult Infectious Diseases + Vancomycin IV³ + Obtain allergy consult for desensitization to ampicillin and ceftriaxone</p>		
Enterococci strains resistant to penicillin	<p>Vancomycin IV³ + Gentamicin IV⁴</p>	6 weeks	
Enterococci strains resistant to vancomycin, aminoglycosides, and penicillin	<p>Daptomycin 10-12 mg/kg IV q24h¹ OR Linezolid: <12 years: 10 mg/kg/dose IV/PO q8h (max: 600 mg/dose) ≥12 years: 10 mg/kg/dose IV/PO q12h (max 600 mg/dose)</p>	>6 weeks	<ul style="list-style-type: none"> Follow baseline and weekly CK with daptomycin therapy. Combination therapy with daptomycin and ampicillin or ceftaroline may be considered in patients with persistent disease
Staphylococci (MSSA)	<p><u>Preferred:</u> Nafcillin 33 mg/kg/dose IV q4h² (max: 2 g/dose)</p>	6 weeks	<ul style="list-style-type: none"> Cefazolin should not be used if CNS disease present.
	<p><u>Alternative for PCN Allergy (non-anaphylaxis):</u> Cefazolin 33 mg/kg/dose IV q8h¹ (max: 2 g/dose)</p>		
	<p><u>Alternative for PCN Allergy (Anaphylaxis):</u> Vancomycin IV³</p>		
Pathogens	Antibiotic Therapy (renal dose adjustments may be necessary)¹	Duration	Comments
Staphylococci (MRSA)	<p><u>Preferred:</u> Vancomycin IV³</p>	6 weeks	<ul style="list-style-type: none"> Follow baseline and weekly CK with daptomycin therapy
	<p><u>Alternative for Vancomycin Allergy or Failure:</u></p>		

	Daptomycin 10 mg/kg IV q24h ¹		
HACEK Group	<u>Preferred:</u> Ceftriaxone 100 mg/kg/dose IV q24h (max: 2 g/dose)	4 weeks	
	<u>Alternative:</u> Ampicillin-sulbactam 75 mg/kg/dose IV q6h ¹ (max: 3 g of ampicillin/dose)		
	<u>Alternative for Severe PCN Allergy:</u> Ciprofloxacin 10 mg/kg/dose IV q8h ¹ (max: 400 mg/dose)		
Candida spp.	<u>Preferred:</u> Liposomal amphotericin B 3-5 mg/kg/dose IV q24h ¹ + Flucytosine 25 mg/kg/dose PO q6h ¹	≥6 weeks	<ul style="list-style-type: none"> • Following initial therapy with IV antifungal agent, long-term suppression with an oral azole may be considered for sensitive pathogens. • Flucytosine may cause myelosuppression and therefore a CBC should be routinely obtained. Consider risk versus benefit of use especially in patients with renal insufficiency. • Flucytosine therapeutic drug monitoring is recommended in all patients - peak level should be drawn after 3-5 days. Goal peak 20-80 mg/L. • <i>Candida parapsilosis</i> demonstrates innately higher MICs to the echinocandins and thus empiric use of micafungin for this organism is not preferred.
	<u>Alternative for Intolerance to Liposomal Amphotericin B/Flucytosine:</u> Micafungin 5 mg/kg/dose IV q24h (max: 150 mg/dose)		
Culture negative (acute, presents within days of symptom onset)	Vancomycin IV ³ + Ceftriaxone 100 mg/kg/dose IV q24h (max: 2 g/dose)	4-6 weeks	<ul style="list-style-type: none"> • Receipt of antibiotics prior to obtaining cultures is the most common cause of culture negative IE. There are many infectious and non-infectious causes. An evaluation of epidemiological factors, history of prior cardiovascular infections, exposure to antimicrobials, clinical course, severity, and extracardiac sites of infection should be performed to help guide diagnosis and treatment. • Gentamicin should be added in patients with a high suspicion for <i>Enterococcus</i> infections. • Cefepime 50 mg/kg/dose IV q8h¹ (max: 2 g/dose) should be used instead of ceftriaxone in burn patients and IV drug users for empiric coverage of <i>Pseudomonas</i>.
Culture negative (subacute, presents within weeks of symptom onset)	Vancomycin IV ³ + Ampicillin-sulbactam 75 mg/kg/dose IV q6h ¹ (max: 3 g of ampicillin/dose) OR Vancomycin IV ³ + Ceftriaxone 100 mg/kg/dose IV q24h (max: 2 g/dose)	4-6 weeks	

Footnotes:

1. Refer to [Antimicrobial Dosing Recommendations for Pediatric Patients](#)
2. If candidate for outpatient therapy, may consider administration via continuous infusion (same daily dose)
3. Refer to [Empiric Dosing and Monitoring Recommendations for Vancomycin in Pediatric Patients](#)
4. Refer to [Empiric Dosing and Monitoring Recommendations for Aminoglycosides in Pediatric Patients](#)

Antimicrobial Subcommittee Approval: 11/2018	Originated: 03/2016
P&T Approval: 11/2018	Last Revised: 03/2021
Revision History: UMHS P&T Antimicrobial Subcommittee: 02/2016, 11/2018; UMHS P&T Committee: 03/2016, 11/2018 03/21: Updated vancomycin and gentamicin hyperlinks	

The recommendations in this guide are meant to serve as treatment guidelines for use at Michigan Medicine facilities. If you are an individual experiencing a medical emergency, call 911 immediately. These guidelines should not replace a provider's professional medical advice based on clinical judgment, or be used in lieu of an Infectious Diseases consultation when necessary. As a result of ongoing research, practice guidelines may from time to time change. The authors of these guidelines have made all attempts to ensure the accuracy based on current information, however, due to ongoing research, users of these guidelines are strongly encouraged to confirm the information contained within them through an independent source.

If obtained from a source other than med.umich.edu/asp, please visit the webpage for the most up-to-date document.